AzTrials
AzTrials

Alzheimer's DiseasePhase 2NCT02880956

A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease

A Phase 2 study testing ABBV-8E12 in people with Alzheimer's Disease, run by AbbVie at 68 sites in 11 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD). Read more about this study

Who is it for?
Ages 55 to 85 years
Conditions the study is for
Alzheimer's Disease
What is being tested?
ABBV-8E12
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
453 participants
Where
68 sitesin 11 countries
Study dates
26 Jan 2017to 28 Jul 2021
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 55 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subject who meets the National Institute on Aging and the Alzheimer's Association (NIA-AA) clinical criteria for mild cognitive impairment or probable AD, and have:
  • Clinical Dementia Rating (CDR)-Global Score of 0.5
  • Mini-Mental State Examination (MMSE) score of 22 to 30, inclusive
  • Repeatable Battery for the Assessment of Neuropsychological Status-Delayed Memory Index (RBANS - DMI) score of 85 or lower
  • Subject has a positive amyloid positron emission tomography (PET) scan.
  • Subject has a Modified Hachinski Ischemic Scale (MHIS) score of ≤ 4.
  • The subject has an identified, reliable, study partner (e.g., family member).
  • If using medications to treat symptoms related to AD, doses must be stable for at least 12 weeks prior to randomization.

Who cannot join

  • Subject has any contraindications or inability to tolerate brain magnetic resonance imaging (MRI), PET scans or lumbar puncture.
  • Subject has evidence of any other clinically significant neurological disorder other than early AD.
  • In the opinion of the investigator, the subject has any clinically significant or uncontrolled medical or psychiatric illness, or has had an infection requiring medical intervention in the past 30 days.
  • Subject has had a myocardial infarction, unstable angina, stroke, transient ischemic attack or required intervention for any of these conditions within 6 months of Screening.

Trial locations and contacts

68 sites in 11 countries.

68 sites in 11 countries

United States38 sites
  • Integrated Neurology Services /ID# 154863

    Alexandria, Virginia, 22310

  • Emory Midtown Infectious Disease Clinic /ID# 151492

    Atlanta, Georgia, 30322

  • Atlanta Center for Medical Research /ID# 151550

    Atlanta, Georgia, 30331

  • Johns Hopkins Bayview Med Cnt /ID# 151893

    Baltimore, Maryland, 21224

  • Massachusetts General Hospital /ID# 151770

    Boston, Massachusetts, 02114

  • Brigham and Women's Physicians /ID# 151882

    Boston, Massachusetts, 02115

  • Great Lakes Clinical Trials /ID# 152754

    Chicago, Illinois, 60640

  • Kerwin Research Center /ID# 147815

    Dallas, Texas, 75231-4316

  • NeuroStudies.net, LLC /ID# 152746

    Decatur, Georgia, 30030

  • Brain Matters Research /ID# 147796

    Delray Beach, Florida, 33445

  • Duke Cancer Center /ID# 147828

    Durham, North Carolina, 27710-3000

  • University of Kansas Medical Center - Alzheimer's Disease Center /ID# 151554

    Fairway, Kansas, 66205

  • Neuropsychiatric Research Center of Southwest Florida /ID# 162332

    Fort Myers, Florida, 33912

  • Hattiesburg Clinic /ID# 202388

    Hattiesburg, Mississippi, 39401

  • Houston Methodist Hospital /ID# 154810

    Houston, Texas, 77030

  • McGovern Medical School /ID# 204860

    Houston, Texas, 77054

  • Indiana University /ID# 151861

    Indianapolis, Indiana, 46202

  • Irvine Clinical Research /ID# 162331

    Irvine, California, 92614

  • Mayo Clinic /ID# 151236

    Jacksonville, Florida, 32224

  • Ucsd /Id# 152467

    La Jolla, California, 92037

  • Scott Research Inc. /ID# 151880

    Laurelton, New York, 11413

  • University of Kentucky Chandler Medical Center /ID# 152753

    Lexington, Kentucky, 40536

  • Vanderbilt University Medical Center /ID# 154547

    Nashville, Tennessee, 37232-0011

  • North Shore University Hospital /ID# 151632

    New Hyde Park, New York, 11040

  • Synexus Clinical Research US, Inc. /ID# 147804

    Orlando, Florida, 32806-1044

  • Advocate Lutheran General Hospital /ID# 152052

    Park Ridge, Illinois, 60068

  • Banner University of Arizona Medical Center Phoenix /ID# 151536

    Phoenix, Arizona, 85006

  • Keystone Clinical Studies LLC /ID# 202305

    Plymouth Meeting, Pennsylvania, 19462

  • Oregon Health and Science University /ID# 151690

    Portland, Oregon, 97239

  • Princeton Medical Institute /ID# 152934

    Princeton, New Jersey, 08540

  • Rhode Island Hospital /ID# 151538

    Providence, Rhode Island, 02903

  • University of Utah /ID# 151858

    Salt Lake City, Utah, 84112-5500

  • Ray Dolby Brain Health Center /ID# 154965

    San Francisco, California, 94113

  • Univ California, San Francisco /ID# 152053

    San Francisco, California, 94143-2204

  • Southern IL Univ School of Med /ID# 151769

    Springfield, Illinois, 62702

  • Banner Sun Health Res Inst /ID# 151895

    Sun City, Arizona, 85351

  • University of South Florida /ID# 151890

    Tampa, Florida, 33612

  • Synexus Clinical Research US, Inc /ID# 151633

    The Villages, Florida, 32162-7116

Other trials in United States

Italy7 sites
  • IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli /ID# 152395

    Brescia, 25125

  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 152401

    Milan, 20122

  • ASST Grande Ospedale Metropolitano Niguarda /ID# 152391

    Milan, 20162

  • AOU di Modena /ID# 152394

    Modena, Emilia-Romagna, 41126

  • Azienda Ospedaliera di Perugia /ID# 152397

    Perugia, Umbria, 06129

  • Policlinico Agostino Gemelli /ID# 152396

    Rome, Lazio, 00168

  • Duplicate_AOU Policlinico Umberto I /ID# 163144

    Rome, Lazio, 00185

Other trials in Italy

Australia6 sites
  • The Kinghorn Cancer Centre /ID# 152632

    Darlinghurst, New South Wales, 2010

  • Austin Health /ID# 152637

    Heidelberg, Victoria, 3084

  • Australian Alzheimer's Res Fou /ID# 152634

    Nedlands, Western Australia, 6009

  • The Royal Melbourne Hospital /ID# 202633

    Parkville, Victoria, 3050

  • Griffith University /ID# 152635

    Southport, Queensland, 4222

  • Neurodegenerative Disorders Research /ID# 152826

    West Perth, Western Australia, 6005

Other trials in Australia

Spain5 sites
  • Fundacio ACE /ID# 152643

    Barcelona, 08028

  • Hospital Clinic de Barcelona /ID# 152646

    Barcelona, 08036

  • Fundacion CITA Alzheimer Fundazioa /ID# 152645

    Donostia / San Sebastian, Basque Country, 20009

  • Hospital Clinico Universitario San Carlos /ID# 153703

    Madrid, 28040

  • Hospital Universitario 12 de Octubre /ID# 152647

    Madrid, 28041

Other trials in Spain

Belgium3 sites
  • Universitair Ziekenhuis Leuven /ID# 152642

    Leuven, Vlaams-Brabant, 3000

  • Groupe Sante CHC - Clinique du MontLegia /ID# 152846

    Liège, 4000

  • UCL Saint-Luc /ID# 152847

    Woluwe-Saint-Lambert, Brussels Capital, 1200

Other trials in Belgium

Canada2 sites
  • Parkwood Institute /ID# 164204

    London, Ontario, N6C 0A7

  • Toronto Memory Program /ID# 147863

    Toronto, Ontario, M3B 2S7

Other trials in Canada

Finland2 sites
  • Ita-Suomen Yliopisto /ID# 152959

    Kuopio, 70210

  • Clinical Research Services Turku /ID# 152845

    Turku, Southwest Finland, 20520

Other trials in Finland

Sweden2 sites
  • Sahlgrenska University Hospital Molndal /ID# 154465

    Mölndal, Västra Götaland County, 431 80

  • Karolinska University Hospital Huddinge /ID# 156705

    Stockholm, Stockholm County, 171 77

Other trials in Sweden

Denmark1 site
  • Rigshospitalet /ID# 153192

    Copenhagen Ø, Capital Region, 2100

Other trials in Denmark

Netherlands1 site
  • Universitair Medisch Centrum Utrecht /ID# 163576

    Utrecht, 3584 CX

Other trials in Netherlands

New Zealand1 site
  • CGM Research Trust /ID# 152827

    Burwood, 8083

Other trials in New Zealand

About this study

Official title: A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease

This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).

Being tested
ABBV-8E12, placebo for ABBV-8E12
Keywords
Early Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), Mild Alzheimer's Disease (AD), Tau, Early dementia, Tauopathies, AD, Neurodegenerative diseases, Memory loss, Nervous system diseases
Medical subject headings
Alzheimer Disease, Cognitive Dysfunction, Pick Disease of the Brain, Dementia, Tauopathies, Neurodegenerative Diseases, Memory Disorders, Nervous System Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ABBV-8E12Drug

    Also called Tilavonemab

    ABBV-8E12 solution for IV infusion

  • placebo for ABBV-8E12Drug

    placebo solution for intravenous (IV) infusion

Study groups in NCT02880956
Study groupRoleWhat they receive
PlaceboPlacebo comparatorPlacebo for ABBV-8E12 every 4 weeks for 96 weeks
Receives: Drug: placebo for ABBV-8E12
ABBV-8E12 300 mgExperimentalABBV-8E12 300 mg every 4 weeks for 96 weeks
Receives: Drug: ABBV-8E12
ABBV-8E12 1000 mgExperimentalABBV-8E12 1000 mg every 4 weeks for 96 weeks
Receives: Drug: ABBV-8E12
ABBV-8E12 2000 mgExperimentalABBV-8E12 2000 mg every 4 weeks for 96 weeks
Receives: Drug: ABBV-8E12

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline Over Time in CDR-SB Score

    The CDR-SB is a numeric scale used to quantify the severity of symptoms of dementia. A qualified health professional assesses a participant's cognitive and functional performance in 6 areas: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. The CDR scale gives a score from 0 to 3 for each of the 6 areas, with a lower value being desirable. The sum of these 6 areas, the CDR-SB score, can range from 0 to 18, with a lower value being desirable.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    A TEAE was defined as an adverse event (AE) that began on or after the first study drug dose date and no more than 20 weeks after the last dose of study drug. An adverse event (AE) was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. Serious AEs (SAEs) were defined as an event that results in death, is life-threatening, results in hospitalization or prolongs hospitalization, is a congenital abnormality, results in persistent or significant disability/incapacity, or is an important medical event. Events were rated in severity as mild, moderate, or severe, and were categorized as having a reasonable possibility or no reasonable possibility of relationship to study drug.

    Measured: From first dose of study drug up to last dose of study drug plus 20 weeks (up to Week 112)

Secondary outcomes (45)
  1. Maximum Observed Serum Concentration (Cmax) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses

    Measured: Day 1 (Dose 1): Pre-infusion, post-infusion (within 15 minutes), 1 and 2 hours post-infusion; Days 5 and 15. Day 85 (Dose 4): Pre-infusion (0 hour), post-infusion (within 15 minutes) and 1 and 2 hours post-infusion; Days 89 and 99.

  2. Time to Cmax (Tmax) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses

    Measured: Day 1 (Dose 1): Pre-infusion, post-infusion (within 15 minutes), 1 and 2 hours post-infusion; Days 5 and 15. Day 85 (Dose 4): Pre-infusion (0 hour), post-infusion (within 15 minutes) and 1 and 2 hours post-infusion; Days 89 and 99.

  3. Serum Concentration at the End of a Dose Interval (Ctrough) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses

    Measured: Day 1 (Dose 1): Pre-infusion, post-infusion (within 15 minutes), 1 and 2 hours post-infusion; Days 5 and 15. Day 85 (Dose 4): Pre-infusion (0 hour), post-infusion (within 15 minutes) and 1 and 2 hours post-infusion; Days 89 and 99.

  4. Half-Life (T1/2) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses

    Harmonic mean is presented in the data table.

    Measured: Day 1 (Dose 1): Pre-infusion, post-infusion (within 15 minutes), 1 and 2 hours post-infusion; Days 5 and 15. Day 85 (Dose 4): Pre-infusion (0 hour), post-infusion (within 15 minutes) and 1 and 2 hours post-infusion; Days 89 and 99.

  5. Area Under the Concentration-Time Curve From Dosing (Time 0) to Day 28 (AUC0-28) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses

    • The AUC0-28 for Dose 1 included the following timepoints: pre-infusion, post-infusion (within 15 min), 1 and 2 hours post-infusion, Day 5, Day 15 and Day 29 (trough level before Dose 2).
    • The AUC0-28 for Dose 4 included the following timepoints: Day 85 pre-infusion, post-infusion (within 15 min), 1 and 2 hours post-infusion, Day 89, Day 99 and Day 113 (trough level before Dose 5).

    Measured: Day 1 (Dose 1): pre-infusion, up to Day 29 (trough level before Dose 2). Day 85 (Dose 4): pre-infusion, up to Day 113 (trough level before Dose 5). See Outcome Measure description above for complete time point details.

  6. Cmax/Dose for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses

    Measured: Day 1 (Dose 1): Pre-infusion, post-infusion (within 15 minutes), 1 and 2 hours post-infusion; Days 5 and 15. Day 85 (Dose 4): Pre-infusion (0 hour), post-infusion (within 15 minutes) and 1 and 2 hours post-infusion; Days 89 and 99.

  7. AUC0-28/Dose for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses

    • The AUC0-28/dose for Dose 1 included the following timepoints: pre-infusion, post-infusion (within 15 min), 1 and 2 hours post-infusion, Day 5, Day 15 and Day 29 (trough level before Dose 2).
    • The AUC0-28/dose for Dose 4 included the following timepoints: Day 85 pre-infusion, post-infusion (within 15 min), 1 and 2 hours post-infusion, Day 89, Day 99 and Day 113 (trough level before Dose 5).

    Measured: Day 1 (Dose 1): pre-infusion, up to Day 29 (trough level before Dose 2). Day 85 (Dose 4): pre-infusion, up to Day 113 (trough level before Dose 5). See Outcome Measure description above for complete time point details.

  8. Change From Baseline Over Time in Alzheimer's Disease Assessment Scale (14-Item) Cognition Portion (ADAS-Cog-14) Total Score

    The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in mild cognitive impairment (MCI) patients. The Total Score of the ADAS-Cog-14 ranges from 0 to 90, with a higher score representing greater impairment.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  9. Change From Baseline Over Time in ADAS-Cog-14 Comprehension of Spoken Language Score

    The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Comprehension of Spoken Language score of the ADAS-Cog-14 ranges from 0 to 5, with a higher score representing greater impairment.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  10. Change From Baseline Over Time in ADAS-Cog-14 Constructional Praxis Score

    The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Constructional Praxis Score of the ADAS-Cog-14 ranges from 0 to 5, with a higher score representing greater impairment.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  11. Change From Baseline Over Time in ADAS-Cog-14 Commands Score

    The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Commands Score of the ADAS-Cog-14 ranges from 0 to 5, with a higher score representing greater impairment.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  12. Change From Baseline Over Time in ADAS-Cog-14 Delayed Word Recall Score

    The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Delayed Word Recall Score of the ADAS-Cog-14 ranges from 0 to 10, with a higher score representing greater impairment.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  13. Change From Baseline Over Time in ADAS-Cog-14 Ideational Praxis Score

    The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Ideational Praxis Score of the ADAS-Cog-14 ranges from 0 to 5, with a higher score representing greater impairment.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  14. Change From Baseline Over Time in ADAS-Cog-14 Maze Task Score

    The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Maze Task Score of the ADAS-Cog-14 ranges from 0 to 5, with a higher score representing greater impairment.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  15. Change From Baseline Over Time in ADAS-Cog-14 Number Cancellation Score

    The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Number Cancellation Score of the ADAS-Cog-14 ranges from 0 to 5, with a higher score representing greater impairment.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  16. Change From Baseline Over Time in ADAS-Cog-14 Naming Score

    The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Naming Score of the ADAS-Cog-14 ranges from 0 to 5 with a higher score representing greater impairment.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  17. Change From Baseline Over Time in ADAS-Cog-14 Orientation Score

    The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Orientation Score of the ADAS-Cog-14 ranges from 0 to 8, with a higher score representing greater impairment.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  18. Change From Baseline Over Time in ADAS-Cog-14 Word Recall - Number of Words Not Recalled Score

    The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Word Recall - Number of Words Not Recalled Score of the ADAS-Cog-14 ranges from 0 to 10, with a higher score representing greater impairment.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  19. Change From Baseline Over Time in ADAS-Cog-14 Remember Word Recognition Instructions Score

    The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Remember Word Recognition Instructions Score of the ADAS-Cog-14 ranges from 0 to 5, with a higher score representing greater impairment.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  20. Change From Baseline Over Time in ADAS-Cog-14 Spoken Language Ability Score

    The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Spoken Language Ability Score of the ADAS-Cog-14 ranges from 0 to 5, with a higher score representing greater impairment.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  21. Change From Baseline Over Time in ADAS-Cog-14 Word Find Difficulty Spontaneous Speech Score

    The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Word Find Difficulty Spontaneous Speech Score of the ADAS-Cog-14 ranges from 0 to 5, with a higher score representing greater impairment.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  22. Change From Baseline Over Time in ADAS-Cog-14 Word Recognition Score

    The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in MCI patients. The Word Recognition Score of the ADAS-Cog-14 ranges from 0 to 12, with a higher score representing greater impairment.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  23. Change From Baseline Over Time in Functional Activities Questionnaire (FAQ) Score

    The FAQ measures level of assistance (functional disability) needed for carrying out instrumental activities in daily living (iADLs). The FAQ score ranges from 0 - 30 and consists of 10 items (each scored from 0 - 3), which measure a specific iADL in the past 4-weeks: [1) writing checks, paying bills, keeping financial records; 2) assembling tax or business records; 3) shopping alone; 4) playing a game of skill; 5) making coffee or tea; 6) preparing a balanced meal; 7) keeping track of current events; 8) attending to and understanding a television program, book, or magazine; 9) remembering appointments, family occasions, medications; and 10) traveling out of the neighborhood]. Performance in each category is rated from 0 - 3 as follows: 0 - normal; 1 - has difficulty, but does by self; 2 - requires assistance; or 3 - dependent. The FAQ was administered by a trained interviewer. Higher scores indicate a greater requirement of assistance.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  24. Change From Baseline Over Time in Alzheimer's Disease Cooperative Study Clinical Global Impression of Change for Mild Cognitive Impairment (ADCS-CGIC-MCI) General Condition Score

    The instrument assesses the physician's global impression of change in 4 major cognitive domains. The instrument covers 4 major domains: 1. General condition , 2. Cognition, 3. Behavior, and 4. Social and daily functioning. Scoring is based on a 7-point Likert Scale: 1, marked improvement; 2, moderate improvement; 3, minimal improvement; 4, no change; 5, minimal worsening; 6, moderate worsening; 7, marked worsening. Higher score indicates greater worsening.

    Measured: Baseline, Week 48, Week 96

  25. Change From Baseline Over Time in ADCS-CGIC-MCI Cognition Score

    The instrument assesses the physician's global impression of change in 4 major cognitive domains. The instrument covers 4 major domains: 1. General condition , 2. Cognition, 3. Behavior, and 4. Social and daily functioning. Scoring is based on a 7-point Likert Scale: 1, marked improvement; 2, moderate improvement; 3, minimal improvement; 4, no change; 5, minimal worsening; 6, moderate worsening; 7, marked worsening. Higher score indicates greater worsening.

    Measured: Baseline, Week 48, Week 96

  26. Change From Baseline Over Time in ADCS-CGIC-MCI Behavior Score

    The instrument assesses the physician's global impression of change in 4 major cognitive domains. The instrument covers 4 major domains: 1. General condition , 2. Cognition, 3. Behavior, and 4. Social and daily functioning. Scoring is based on a 7-point Likert Scale: 1, marked improvement; 2, moderate improvement; 3, minimal improvement; 4, no change; 5, minimal worsening; 6, moderate worsening; 7, marked worsening. Higher score indicates greater worsening.

    Measured: Baseline, Week 48, Week 96

  27. Change From Baseline Over Time in ADCS-CGIC-MCI Functional Abilities Score

    The instrument assesses the physician's global impression of change in 4 major cognitive domains. The instrument covers 4 major domains: 1. General condition , 2. Cognition, 3. Behavior, and 4. Social and daily functioning (functional abilities). Scoring is based on a 7-point Likert Scale: 1, marked improvement; 2, moderate improvement; 3, minimal improvement; 4, no change; 5, minimal worsening; 6, moderate worsening; 7, marked worsening. Higher score indicates greater worsening.

    Measured: Baseline, Week 48, Week 96

  28. Change From Baseline Over Time in University of California's Performance Based Skills Assessment, Brief Version (UPSA-Brief) - Total Score

    The UPSA-Brief is a performance-based instrument which uses a series of tasks and roleplay scenarios to evaluate a person's functional capacity in two areas of basic living skills (i.e., financial skills and communication skills). Scores range from 0 to 100; a higher score of the UPSA-Brief is desirable.

    Measured: Baseline, Week 48, Week 96

  29. Change From Baseline Over Time in 24-Item Alzheimer's Disease Cooperative Study/Activities of Daily Living Scale Adapted for Patients With Mild Cognitive Impairment (ADCS-MCI-ADL-24) Total Score

    The ADCS-MCI-ADL-24 is a 24-item, study partner-based assessment of activities of daily living designed specifically for AD patients and is completed by a trained rater. The scale assesses functional activities such as cooking, household chores, shopping, keeping appointments, social interactions and hobbies. Items are assessed according to whether they were performed in the past 4 weeks and, if so, some items are further assessed as to whether they were performed independently, with supervision, or with physical help. Scores on the ADCS-ADL-MCI range from 0 to 69, where higher score indicates greater capability to carry out activities of daily living.

    Measured: Baseline, Week 48, Week 96

  30. Change From Baseline Over Time in Repeatable Battery for Assessment of Neuropsychological Status (RBANS) - Total Scale Score

    The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. Total score can range from 40 to 160 with a higher score representing a better outcome.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  31. Change From Baseline Over Time in RBANS - Coding Total Score

    The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The Coding Total Score of the RBANS ranges from 0 to 89, with a higher score representing a better outcome.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  32. Change From Baseline Over Time in RBANS - Digit Span Total Score

    The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The Digit Span Total Score of the RBANS ranges from 0 to 8, with a higher score representing a better outcome.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  33. Change From Baseline Over Time in RBANS - Figure Copy Total Score

    The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The Figure Copy Total Score of the RBANS ranges from 0 to 20, with a higher score representing a better outcome.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  34. Change From Baseline Over Time in RBANS - Figure Recall Total Score

    The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The Figure Recall Total Score of the RBANS ranges from 0 to 18, with a higher score representing a better outcome.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  35. Change From Baseline Over Time in RBANS - List Recognition Total Score

    The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The List Recognition Total Score of the RBANS ranges from 0 to 20, with a higher score representing a better outcome.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  36. Change From Baseline Over Time in RBANS - List Learning Total Score

    The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The List Learning Total Score of the RBANS ranges from 0 to 40, with a higher score representing a better outcome.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  37. Change From Baseline Over Time in RBANS - Line Orientation Total Score

    The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The Line Orientation Total Score of the RBANS ranges from 0 to 20, with a higher score representing a better outcome.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  38. Change From Baseline Over Time in RBANS - List Recall Total Score

    The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The List Recall Total Score of the RBANS ranges from 0 to 10, with a higher score representing a better outcome.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  39. Change From Baseline Over Time in RBANS - Picture Naming Total Score

    The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The Picture Naming Total Score of the RBANS ranges from 0 to 10, with a higher score representing a better outcome.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  40. Change From Baseline Over Time in RBANS - Semantic Fluency Total Score

    The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The Semantic Fluency Total Score of the RBANS ranges from 0 to 40, with a higher score representing a better outcome.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  41. Change From Baseline Over Time in RBANS - Story Memory Total Score

    The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The Story Memory Total Score of the RBANS ranges from 0 to 24, with a higher score representing a better outcome.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  42. Change From Baseline Over Time in RBANS - Story Recall Total Score

    The RBANS is a 25-minute, standardized neurocognitive battery with North American population-based normative data. The RBANS measures five neurocognitive domains, with age-based scaling. Twelve subtests measure cognitive decline or improvement across the following domains: 1. Immediate Memory - List Learning and Story Memory, 2. Visuospatial/Constructional - Figure Copy and Line Orientation, 3. Language - Picture naming and Semantic Fluency, 4. Attention - Digit Span and Coding, and 5. Delayed Memory - List Recall, List Recognition, Story Memory, and Figure Recall. The Story Recall Total Score of the RBANS ranges from 0 to 12, with a higher score representing a better outcome.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  43. Change From Baseline Over Time in Mini-Mental State Examination (MMSE) Total Score

    The MMSE is a brief, 30-point questionnaire, administered by a trained rater, which provides a quantitative measure of cognitive status in adults and is widely used to screen for cognitive impairment and to estimate the severity of cognitive impairment at a given point in time in AD participants. The MMSE ranges from 0 to 30, with lower scores indicating greater impairment.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  44. Change From Baseline Over Time in Neuropsychiatry Inventory (NPI) Total Score

    The NPI is used to assess changes in the participant's behavior that occurred in a defined period of time (4 weeks). The NPI assesses 12 behavioral domains on the dimensions of frequency and severity. Frequency is rated on a scale where 0 = absent, 1 = occasionally, 2 = often, 3 = frequently, 4 = very frequently. Severity is rated on a scale where 0 = absent, 1 = mild, 2 = moderate, 3 = severe. For each of the domains, 3 scores are obtained: frequency, severity, and total (product of frequency and severity; ranges from 0 to 12, with a lower score desirable). A total NPI score can be calculated by summing the domain total scores. Total Score ranges from 0 to 144 with a lower score desirable.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

  45. Change From Baseline Over Time in Alzheimer's Disease Composite Score (ADCOMS) Score

    ADCOMS score is a composite score which is a weighted linear combination of the selected individual scale items from ADAS-Cog-14 (see description in Outcome Measure 10) , MMSE (see description in Outcome Measure 45), and CDR-SB (see description in Outcome Measure 1) scales. The ADCOMS score ranges from 0 to 1.97, with a lower score desirable.

    Measured: Baseline, Week 24, Week 48, Week 72, Week 96

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Aug 2016 (estimated)
  2. Study start26 Jan 2017
  3. Primary completion30 Mar 2021
  4. Study completion28 Jul 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
453 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02880956
Sponsor's protocol ID
M15-566
Other IDs
2016-001634-10, 2016
Status last verified
Aug 2022
First submitted
24 Aug 2016
Last updated
26 Aug 2022
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Expanded access
Available

Publications

  • Wang D, Florian H, Lynch SY, Robieson W, Zhuang R, Kusiak C, Ross JL, Walsh JR, Graff O. Using AI-generated digital twins to boost clinical trial efficiency in Alzheimer's disease. Alzheimers Dement (N Y). 2025 Nov 22;11(4):e70181. doi: 10.1002/trc2.70181. eCollection 2025 Oct-Dec.

    PubMed 41281734

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing ABBV-8E12 in people with Alzheimer's Disease, run by AbbVie at 68 sites in 11 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 68 sites in United States, Italy, Australia, Spain, Belgium and 6 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 26 Aug 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline Over Time in CDR-SB Score (time frame: Baseline, Week 24, Week 48, Week 72, Week 96). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02880956, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in